Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 8: HOPE study results: primary end point Abb. 9: HOPE study results: secondary end point Abb. 10: ONTARGET - Rationale Aktuelles Bild - Abb. 11: ONTARGET - rationale Abb. 12: ONTARGET - rationale Abb. 13: ONTARGET - objectives Abb. 14: ONTARGET - a global trial Zum letzten Bild
Abbildung 11: ONTARGET - rationale
During chronic treatment with ACE inhibitors, some patients may experience a reactive, persistent and detrimental increase in angiotensin II levels due to compensatory stimulation of alternative pathways of angiotensin II formation, a phenomenon known as angiotensin II escape. Angiotensin II escape is a marker of poor cardiovascular outcome.
 
ONTARGET - rationale
Vorheriges Bild Nächstes Bild   


Abbildung 11: ONTARGET - rationale
During chronic treatment with ACE inhibitors, some patients may experience a reactive, persistent and detrimental increase in angiotensin II levels due to compensatory stimulation of alternative pathways of angiotensin II formation, a phenomenon known as angiotensin II escape. Angiotensin II escape is a marker of poor cardiovascular outcome.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung